Articles On Immuron (ASX:IMC)

Cynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biotechs need to do to commence a clinical trial Which ASX biotechs have an IND submission to the FDA and will start a clinical trial soon?   Wh...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan. 

Good news is bad news for the US economy Aussie benchmark goes deep into a pre-Christmas shame spiral Ho ho oh s%#$! What just happened?   The Closing Jingle Bell has rung, so that’s it until after Christmas for 2022! What a pity today’s...

Immuron’s (IMC) lands US Food and Drug Administration (FDA) approval for its investigational new drug application for its Travelan product With the approval in hand, IMC can proceed with its clinical trial assessing the safety and effica...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Dr Boreham’s Crucible By Tim Boreham ASX code: ((IIQ)) Share price: 67 cents Market cap: $59.8 million Shares on issue: 92,018,702 Chief executive officer: Dr Leearne Hinch Board: Dr Geoffrey Cumming (chair), Robert (Max) Johnston, Philip P...

Immuron (IMC) will deprioritise its SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates Immuron entered the new financial year with a newly appointed CEO at its helm, who has been working to complete...

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received feedback from the US FDA following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ET...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Biopharmaceutical company Immuron (IMC) sees a 494 per cent increase in North American Travelan sales for FY22 Sales totalled $600,000 for the financial year, up from the $100,000 recorded in FY21 while US sales were up from the $4000 reco...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has submitted an Investigational New Drug application to the US FDA for a new oral therapeutic targeting Campylobacter and ETEC.

Immuron’s (IMC) travellers diarrhoea preventative medication Travelan is set to be tested for efficacy to inform strategies for defence force health protection The study is being conducted by the US Department of Defense Uniformed Services...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Highlights The Australian healthcare sector includes companies engaged in biotechnology and research, food and drug retailing, health care equipment, service providers, and pharmaceuticals. On a YTD basis, the healthcare index is runni...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Things weren’t looking good ahead of the opening bell today, after a rough session for US stocks following another rise in bond yields overnight. And that bearish momentum flowed through to the ASX 200, which posted its second +1% fall in f...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week There’s so...

The Immuron Ltd (ASX: IMC) share price soared again today, trading up 16.67% at 14 cents near the market close. This follows a massive trading day as the company cemented its place as one of the best performers on the ASX yesterday with i...

Immuron (IMC) is granted a European patent for compositions and methods for treating travellers’ diarrhoea  Immuron’s Travelan is an orally administered immunotherapy that reduces the likelihood of contracting travellers’ diarrhoea – prove...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

ASX investors got back in the risk saddle on Wednesday, with steady gains across the large cap indexes and a 1.7% jump for the microcap Emerging Companies index. The catalyst appeared to be comments from US Fed Chair Jerome Powell overnight...

The Australian share market has recovered after two days of losses with Energy and Materials stocks leading the charge. The S&P/ASX 200 Index has clawed back 47 points, or 0.64 per cent, to 7437.10, making up for most of yesterday’s...

The ASX has jumped out of the blocks this morning, as expected, after two consecutive days of losses. The S&P/ASX 200 Index has risen 35.8 points, or 0.48 per cent, to 7,425.90. What’s driving the market The Nasdaq continued...

Immuron nabs $6.2m clinical research deal for US Military strength Travelan dose ECS Botanics reports record revenue of $1.5m expected for Q2 FY22 Compumedics secures first major magnetoencephalography (MEG) sale in China Immuron (ASX:IMC...

The Immuron Ltd (ASX: IMC) share price is shooting out the lights on Wednesday following a positive update from the company. At the time of writing, the biopharma company’s shares are swapping hands for 12.2 cents, up 31.18%. A clinical-st...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

Immuron (ASX:IMC) has announced the restart of its clinical development program that was temporarily halted due to the COVID-19 pandemic.

The ASX retreated again as angst over inflation and the withdrawal of stimulus continued to weigh on global markets. The ASX 200 closed at 7,300 – 0.28% lower than Friday’s close. Tech was the biggest laggard, losing nearly 3% but energy an...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain to 1.9%. All sectors gained with the best being resources which gained nearly 1.7%. Australia’s rise was in line with the broader Asia-Pacifi...

The Immuron Ltd (ASX: IMC) share price is taking off today after it was found the company’s drug might be able to treat COVID-19. Researchers from the Hebrew University’s Hadassah Medical Center tested if the company’s proprietary product,...

The ASX 200 health stocks index (XHJ) had risen by 0.30% at the time of writing, compared to the broader ASX 200 index which is up by 0.74%. Immuron (ASX:IMC) jumped 19% this morning, after announcing a recent publication of the potential a...

Immuron (ASX:IMC) has announced it will not proceed with a previously announced acquisition of a private company focused on the development of vaccine technologies.

The ASX limped into the close on Friday, in a fairly tame finish to a roller-coaster week. Evergrande contagion fears and jitters ahead of the US Fed meeting sparked a sharp selloff on Monday. But a week (or three days) is a long time in ma...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...